Overall, at Week 52, more than 60% of patients were free of flares1. Additionally, more than 50% experienced a meaningful reduction in pain, which has […]
Novartis today announced the Phase III APPOINT-PNH study (NCT04820530) of investigational oral monotherapy iptacopan in complement-inhibitor-naïve (including anti-C5 therapies) adults with PNH met its primary […]
Ad hoc announcement pursuant to Art. 53 LR Today, Novartis announced the pivotal Phase III PSMAfore study with PluvictoTM (INN: lutetium (177Lu) vipivotide tetraxetan), a […]
Ad hoc announcement pursuant to Art. 53 LR Q3 sales grew +4% cc1 (-4% USD) Innovative Medicines (IM) sales grew +4% cc (-3% USD), driven […]
Ad hoc announcement pursuant to Art. 53 LR Phase III APPLY-PNH trial met its two primary endpoints for superiority versus anti-C5 treatment in adult paroxysmal […]
Treatment with targeted therapies Tafinlar + Mekinist resulted in 47% ORR versus chemotherapy (11%) and reduced risk of progression or death by 69%, showing significant […]
Complete and overall response rates and durability of response were well maintained across majority of high-risk subgroups with a significant unmet need1 Median follow-up of […]
Updated 48-week data from Phase III ASCEMBL trial consistent with improved major molecular response (MMR) rate of Scemblix® (asciminib) vs. Bosulif®* (bosutinib) and lower discontinuation […]
Data from the MONALEESA Phase III program provide further evidence of the unique profile of Kisqali, the CDK4/6 inhibitor with the longest reported median overall […]
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it completed the repurchase of Roche shares that had been held by Novartis. On 4 November […]
• Novartis enters into exclusive worldwide license with Mesoblast to develop, commercialize and manufacture remestemcel-L for treatment of acute respiratory distress syndrome (ARDS) and other […]
• If approved, Xolair® (omalizumab) will provide patients who have severe chronic rhinosinusitis with nasal polyps, not adequately controlled by intranasal corticosteroids, with the first […]
• EMA CHMP positive opinion paves way for Cosentyx® to become a first-line systemic treatment in pediatric psoriasis • CHMP opinion based on two Phase […]
Novartis has reached settlements with the US Department of Justice (DOJ) and the US Securities and Exchange Commission (SEC) resolving all Foreign Corrupt Practices Act […]
• FDA approval for Cosentyx® is based on the Phase III PREVENT trial, demonstrating efficacy in active non-radiographic axial spondyloarthritis (nr-axSpA), which is part of […]
Copyright © 2023 | WordPress Theme by MH Themes
